- Home
- Anticoagulation Academy
Professor Gregory Lip highlights the benefits of dabigatran (NOACs) for AF patients requiring anticoagulation therapy while citing evidence from some key clinical trial studies and real-world data of dabigatran showing a significant relative risk reduction in ischemic stroke, systemic embolism, intracranial hemorrhage and all-cause mortality when compared to OACs or other NOACs. The availability of idarucizumab, a specific dabigatran reversal agent adds greater control and is an important factor in oral anticoagulation therapy.
Professor Gregory Lip highlights the benefits of dabigatran (NOACs) for AF patients requiring anticoagulation therapy while citing evidence from some key clinical trial studies and real-world data of dabigatran showing a significant relative risk reduction in ischemic stroke, systemic embolism, intracranial hemorrhage and all-cause mortality when compared to OACs or other NOACs. The availability of idarucizumab, a specific dabigatran reversal agent adds greater control and is an important factor in oral anticoagulation therapy.
The Anticoagulation Webinar is entitled Clinical Trial Data, AF Guidelines and Real World Evidence in SPAF discusses the developments in the field of anticoagulation care, latest available Guidelines in SPAF appreciation of Current Phase 3 data and Real World Evidence in SPAF. The meeting provided a platform to discuss how clinical evidences, updated clinical practice Guidelines in AF and Individual Risk factors are important considerations in the safe and appropriate use of NOACs for SPAF.
A yearly Speakers Meeting that discusses the Advances in anticoagulation care, the complimentary Value of Real World Evidence to Phase III Clinical trial data of Dabigatran and the Essential role of Reversal Agents like Idarucizumab in the management of SPAF patients.
The medical speaker forum for stroke prevention in atrial fibrillation 2021 aimed to discuss the latest development in the field of anticoagulation and updates in the use of specific reversal agents for patients on NOAC. The meeting provided a platform to discuss with Regional Medical Experts how this latest clinical data impacts current clinical practice within the ASEAN and SK region with the aim of ensuring the appropriate use of NOACs for better patient care. It is also provided opportunity for sharing Patient Cases and how current data supports the use of NOACs for the right patient at the appropriate dose.
